Literature DB >> 8882671

Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin.

K Stark1, R Müller, U Bienzle, I Guggenmoos-Holzmann.   

Abstract

OBJECTIVE: To determine whether frontloading (i.e., syringe-mediated drug-sharing) is a risk factor for HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among injecting drug users (IDU).
DESIGN: Cross-sectional study. Data on sociodemographic and behavioural characteristics were obtained by a standardized questionnaire. Serum samples were tested for seromarkers for HIV, HBV and HCV. SETTING AND PARTICIPANTS: IDU were recruited at 'low-threshold' storefront agencies (out-of-treatment sample), and at a centre for long-term drug use treatment (in-treatment sample). Individuals were included in the study if they had injected drugs within the previous 3 months. MAIN OUTCOME MEASURES: Serological evidence for HIV, HBV, HCV exposure.
RESULTS: Of all IDU (n = 324), 84% had ever practised frontloading with non-sterile injecting equipment, and 46% had done so more than 100 times; 32% had front-loaded during the 6 months prior to the interview. The crude seroprevalence rates for HIV, HBV and HCV increased with the overall frequency of frontloading, and reached 22, 71 and 94%, respectively, among IDU who had frontloaded more than 100 times. After controlling for confounding effects by logistic regression, having practised frontloading more than 100 times was significantly associated with HIV infection [adjusted prevalence odds ratio (POR) 3.5; 95% confidence interval (CI), 1.4-9], and HCV infection (adjusted POR, 5.4; 95% CI, 2.3-12), but not with HBV infection. Another independent risk factor for all three virus infections was needle-sharing in prison.
CONCLUSIONS: In communities where sterile injection equipment is readily available, and IDU have substantially reduced their overall levels of needle-sharing, the practice of frontloading appears to be a major risk factor for infections by blood-borne viruses among IDU. Prevention activities should specifically address this risk behaviour.

Entities:  

Mesh:

Year:  1996        PMID: 8882671

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  14 in total

1.  Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.

Authors:  J Lorvick; A H Kral; K Seal; L Gee; B R Edlin
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City.

Authors:  Chi-Chi N Udeagu Pratt; Denise Paone; Rosalind J Carter; Marcelle C Layton
Journal:  Am J Public Health       Date:  2002-08       Impact factor: 9.308

3.  A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.

Authors:  K Stark; U Herrmann; S Ehrhardt; U Bienzle
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

4.  HCV status knowledge and risk behaviours amongst intravenous drug users.

Authors:  G Vidal-Trécan; J Coste; I Varescon-Pousson; B Christoforov; A Boissonnas
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

5.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

6.  Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users.

Authors:  J R Pallás; C Fariñas-Alvarez; D Prieto; M Delgado-Rodríguez
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

7.  Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City.

Authors:  T Diaz; D C Des Jarlais; D Vlahov; T E Perlis; V Edwards; S R Friedman; R Rockwell; D Hoover; I T Williams; E R Monterroso
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

8.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

9.  Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study.

Authors:  Vu Minh Quan; Vivian F Go; Le Van Nam; Anna Bergenstrom; Nguyen Phuong Thuoc; Jonathan Zenilman; Carl Latkin; David D Celentano
Journal:  AIDS Care       Date:  2009-01

10.  A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.

Authors:  Marie Jauffret-Roustide; Yann Le Strat; Elisabeth Couturier; Damien Thierry; Marc Rondy; Martine Quaglia; Nicolas Razafandratsima; Julien Emmanuelli; Gaelle Guibert; Francis Barin; Jean-Claude Desenclos
Journal:  BMC Infect Dis       Date:  2009-07-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.